ʻO ka Lambda Variant: Resistant Vaccine a ʻoi aku ka lele?

KA HOOHOLO

Ke kū nei ka hoʻoili kiʻekiʻe ʻo SARS-CoV-2 ma Chile ʻoiai he hoʻolaha hoʻolaha hoʻoikaika kino, e hilinaʻi nui nei i ka maʻi virus inactivated mai Sinovac Biotech a i kahi liʻiliʻi loa i ka maʻi mRNA mai Pfizer/BioNTech a me nā maʻi viral vector non-replicative mai. ʻO Oxford/AstraZeneca a me Cansino Biologicals.

ʻO ka piʻi hope loa i hōʻike ʻia ma ka ʻāina ua hoʻomalu ʻia e ka SARS-CoV-2 mau ʻano Gamma a me Lambda, ka mea i helu mua ʻia he ʻano hopohopo i kekahi mau mahina i hala aku nei a ʻo ka mea hope i ʻike ʻia he ʻano hoihoi e ka WHO. ʻOiai he 11 mau mutations ka Gamma i loko o ka protein spike me nā mea i loko o ka receptor-binding domain (RBD) e pili ana me ka hoʻonui ʻia ʻana o ka ACE2 paʻa a me ka infectivity (N501Y) a i ʻole ka pakele ʻana (K417T a me E484K) he ʻano kūʻokoʻa ka spike protein o ka ʻano Lambda. kumu o 7 mutation (Δ246-252, G75V, T76I, L452Q, F490S, D614G, T859N) mai ia L452Q i like me ka L452R mutation i hoikeia ma ka Delta a me Epsilon mau ano.

Ua hōʻike ʻia ka hoʻololi ʻana o ka L452R e hāʻawi i ka pakele ʻana i nā antibodies monoclonal (mAbs) a me ka plasma convalescent.

Eia kekahi, ua hōʻike ʻia ka mutation L452R e hoʻonui i ka infectivity viral a hōʻike kā mākou ʻikepili e hiki i ka mutation L452Q i loaʻa i ka ʻano Lambda ke hāʻawi i nā waiwai like me nā mea i wehewehe ʻia no L452R. ʻO ka mea e mahalo ai, aia ka holoi ʻana o 246-252 i ka N-terminal domain (NTD) o ka Lambda Spike i kahi antigenic supersite a no laila, hiki i kēia holoi ʻana ke kōkua pū i ka pakele. Eia kekahi, ua pili pū ka mutation F490S me kahi pakele i ka convalescent sera.

E like me kēia mau mea mua, hōʻike kā mākou hopena i ka spike protein o ka ʻano Lambda e hāʻawi i ka pakele i ka pale ʻana i nā antibodies i hoʻoiho ʻia e ka kano CoronaVac. ʻAʻole ʻike ʻia ka ʻokoʻa Lambda i ka pane kelepona i hōʻike ʻia e CoronaVac.

Ua ʻike pū mākou i ka spike protein o ka ʻano Lambda i hoʻonui i ka infectivity ke hoʻohālikelike ʻia me ka protein spike o nā ʻano Alpha a me Gamma, ʻo lāua ʻelua me ka piʻi ʻana o ka infectivity a me ka transmissibility.

E hui pū, hōʻike kā mākou ʻikepili no ka manawa mua i loaʻa nā mutations i loko o ka protein spike o ka ʻano Lambda e hāʻawi i ka pakele i ka neutralizing antibodies a me ka hoʻonui ʻana i ka infectivity. ʻO nā hōʻike i hōʻike ʻia ma ʻaneʻi e hoʻoikaika i ka manaʻo o ka hoʻolaha ʻana i ka maʻi maʻi nui ma nā ʻāina me ka kiʻekiʻe o ka SARS-CoV-2 circulation rate pono e hui pū ʻia me ka nānā genomic koʻikoʻi i manaʻo ʻia e hoʻomaopopo koke i nā mea hoʻokaʻawale viral hou e lawe ana i nā mutations spike a me nā noiʻi e manaʻo e nānā i ka hopena o kēia. ka hoʻololi ʻana i ka pale ʻana i ka pale ʻana a me ka holomua o nā lāʻau lapaʻau.

Ke holo wikiwiki nei ka COVID-19. Hiki ke ʻike ʻia kēia ma Hawaiʻi kahi helu haʻahaʻa a lele i ka moʻolelo kiʻekiʻe me ka ulu ʻana o ka mākaʻikaʻi.